A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer, the SYNERGY-201 Trial

Syntrix Biosystems, Inc.

Summary

The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed prior therapy with androgen receptor pathway inhibitors.

Eligibility

Age range: 18+ years
Sex: Male
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: 1. Signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent form prior to beginning study and undergoing procedures. 2. 2\. Diagnosis of mCRPC with (a) any histology, and (b) currently on or previously on abiraterone/prednisone (or abiraterone/dexamethasone) or darolutamide, apalutamide or enzalutamide with documented progression in either the mCRPC or mHSPC settings, and currently with: * rising PSA (a rising PSA requires at least 3 measurements obtained at least 1 week apart showing increase from nadir with the la…

Locations (6)

University of California, Los Angeles
Los Angeles, California
ravazquez@mednet.ucla.edu
University of California, San Francisco
San Francisco, California
cody.pham@ucsf.edu
University of Michigan
Ann Arbor, Michigan
clinicaltrials@syntrixbio.com
University of Minnesota
Minneapolis, Minnesota
clinicaltrials@syntrixbio.com
Duke University
Durham, North Carolina
julia.hurrelbrink@duke.edu
University of Wisconsin
Madison, Wisconsin
cancerconnect@uwcarbone.wisc.edu 800-622-8922

Summary

Eligibility

Interventions

Locations (6)